Partnership aims to bring C2N’s portfolio of Alzheimer’s blood testing products to more than 75 countries.
Alzheimer’s blood test developer C2N Diagnostics has signed a partnership with European diagnostic services giant Unilabs, which plans to offer the US-firm’s portfolio of blood tests in more than 75 countries around the world. The multi-year agreement gives Unilabs exclusive access to C2N’s Precivity blood tests across key regions in Europe, the Gulf Region and Latin America.
The collaboration addresses the rising incidence of Alzheimer’s disease by providing less invasive and more accessible diagnostic procedures, allowing more patients to benefit from early detection and personalized treatment strategies. Leveraging C2N’s proprietary Alzheimer’s blood biomarkers, Unilabs aims to establish a testing network across Europe, so that Precivity testing can be performed to the same standard as at C2N’s US laboratory.
“All too often, diagnosing Alzheimer’s has been painful, invasive and expensive,” said Unilabs’ Head of Innovation Dr Rahul Chaudhary. “This partnership will transform the diagnostic experience for patients with cognitive concerns while revolutionizing early diagnosis, and research efforts, and positively impacting long-term outcomes.”
The PrecivityAD blood test has already achieved the CE Mark from the European Union and has been approved by the UK’s Medicines and Healthcare Products Regulatory Agency as an in vitro diagnostic tool. The test aids in the evaluation of patients with mild cognitive impairment or dementia, identifying the likelihood of amyloid plaques and neurofibrillary ‘tau’ tangles in the brain, which are hallmarks of Alzheimer’s disease.
The PrecivityAD test is expected to be part of a future Brain Health Panel offered by C2N, which will measure multiple pathological markers for Alzheimer’s disease and related disorders. The company says that additional markers of Alzheimer’s disease, including p-tau217, are currently in development at its labs.
C2N Diagnostics’ CEO, Dr Joel Braunstein, cited the global impact of Alzheimer’s disease and the importance of improving worldwide access to cutting-edge diagnostics.
“We believe this collaboration allows for the acceleration of equitable access to the highest quality blood biomarkers that can aid in the diagnosis of Alzheimer’s disease,” he said. “To date, we’ve secured other international arrangements and now, we’re very proud to enter this multi-faceted strategic affiliation with Unilabs, an organization that places a premium on quality in testing and in personalized diagnostics for Alzheimer’s disease.”
